Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Heartseed, Inc. ( (JP:219A) ) has provided an update.
Heartseed, Inc. announced the termination of its partnership with Novo Nordisk A/S, clarifying that no penalty will be incurred from the termination. The company retains its milestone payments and continues its development plans for its therapeutic programs in Japan, with no impact on its financial stability for upcoming clinical trials. The overseas strategy is under review, and the company will disclose further information in due course. Despite concerns about potential information leaks and stock trading volumes, Heartseed asserts no correlation between these events and the termination announcement.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed, Inc. operates in the biotechnology industry, focusing on the development of regenerative medicine products. The company specializes in creating allogeneic iPS cell-derived cardiomyocyte spheroids for the treatment of severe heart failure, with a market focus on both Japan and international territories.
Average Trading Volume: 852,398
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen74.11B
See more insights into 219A stock on TipRanks’ Stock Analysis page.